MedTrace Logo

The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors

NCT01224509 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2010-10-20

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of mifepristone on the expression of three cervical EP3 receptor isoforms (EP3-2, EP3-3 and EP3-6) in pregnant women ≤63 days gestational age.

Conditions

  • Cervical Prostaglandin EP3 Receptors
  • Pregnancy

Interventions

DRUG

Mifepristone

Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity

OTHER

Non-treatment

Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity

Sponsors & Collaborators

  • University of Southern California

    lead OTHER

Principal Investigators

  • Marie-Soleil Wagner, MD · University of Southern California

  • John K Jain, MD · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01224509 on ClinicalTrials.gov